课题基金 / 基金详情

Whole-genome sequence analysis of Mycobacteria tuberculosis bacteria to identify the genetic determinants and mechanisms of anti-tuberculosis drug

Whole-genome sequence analysis of Mycobacteria tuberculosis bacteria to identify the genetic determinants and mechanisms of anti-tuberculosis drug
结核分枝杆菌的全基因组序列分析,以确定抗结核药物的遗传决定因素和机制
批准号:
1923132
负责人:
金额:
$0.0万
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
结核病(TB)是一个主要的公共卫生问题。结核分枝杆菌菌株的出现对用于治疗结核病的药物产生了抗药性,这有可能使控制结核病的努力脱轨。对至少两种一线药物的耐药性被称为耐多药结核病(MDR-TB),而对用于治疗MDR-TB的任何药物的额外耐药性被称为广泛耐药结核病(XDR-TB)。这些菌株的出现使临床药物选择复杂化,这沿着药物的相当大的毒性和副作用,导致不良结果、较低的依从性并最终可放大耐药性。因此,早期发现耐药菌株至关重要。临床样本的药敏试验传统上是通过表型方法进行的,这种方法成本高,可能需要数周时间,因为它们涉及培养和操纵高度传染性的细菌。对于某些一线药物,也有基于分子的检测,但大多数敏感性较低。抗药性几乎完全是由编码靶点或药物激活酶的基因的点突变、插入和缺失积累而产生的。基因型与表型相关性的研究使耐药标志物突变库的建立成为可能,因此,临床样本全基因组序列分析与突变库相结合,可以比表型方法更及时地为临床药物管理提供信息。然而,挑战之一是实现痰液样品的直接分析,对于痰液样品,在测序之前仍然需要培养细菌。一种被称为选择性全基因组扩增(SWGA)的方法是一种潜在的解决方案,并且能够通过使用不与非结核分枝杆菌退火的特异性引物从复杂样品中扩增结核分枝杆菌靶基因组。在此基础上,本项目的目标是:(i)应用基于回归-2的模型,从全基因组序列数据中识别新的耐药突变和抗结核药物耐药机制;(ii)利用蛋白质结构模型,验证突变对蛋白质稳定性和药物对接的影响;(iii)发展定量方法,从全基因组序列数据快速预测耐药性。为了实现这些目标,将获得强大的生物信息学和大数据分析技能,并将其应用于基因组学领域。将获得跨学科技能,包括M.结核病和SWGA方法的发展。最后,该项目的结果可能导致新的诊断工具,协助结核病的管理,并最终造福于公共卫生。圣乔治医院和大学的参与将有助于在临床环境中推出任何测序或基于实验室的工具。
英文摘要
resistance.Tuberculosis disease (TB) is a major public health problem. The emergence of Mycobacteriumtuberculosis strains resistant to the drugs used to treat the disease threatens to derail efforts tocontrol TB. Resistance to at least two of the first line drugs is denoted as multidrug-resistanttuberculosis (MDR-TB), whilst additional resistance to any drug used to treat MDR-TB is known asextensively drug-resistant tuberculosis (XDR-TB). The appearance of these strains has complicatedclinical drug selection, which along with the considerable toxicity and side effects of the drugs resultin poor outcomes, less compliance and ultimately can amplify resistance. For this reason, earlydetection of resistant strains is crucial. Susceptibility tests of clinical samples have been traditionallycarried out by phenotypic methods, which are costly and can take weeks since they involve cultureand manipulation of highly infectious bacteria. For some first-line drugs there are also molecularbasedtests, but most have low sensitivity.Drug resistance is conferred almost exclusively by accumulation of point mutations and insertionsand deletions in genes encoding targets or drug-activating enzymes. The study of genotypephenotypeassociations has enabled the creation of a mutation library for drug resistance markers.Therefore, the use of whole-genome sequence analysis of clinical samples in combination with amutation library can inform clinical drug management, in a more timely fashion than phenotypicmethods. Nevertheless, one of the challenges is implement the direct analysis of sputum samples,for which culture of the bacteria prior to sequence is still necessary. A method known as selectivewhole-genome amplification (SWGA) is a potential solution, and enables the amplification of the M.tuberculosis target genome from a complex sample by using specific primers that do not anneal tonon- M. tuberculosis meta genomes in the sputum.On this basis, the aims of this project are: (i) to identify novel resistance mutations and mechanismsof anti-tuberculosis drug resistance from whole-genome sequence data by applying regression-2based models; (ii) to characterise the effects of mutations on protein stability and drug docking byusing protein structure models; (iii) to develop quantitative methods to rapidly predict drugresistance from whole genome sequence data. In order to accomplish these aims, strongbioinformatics and big data analysis skills will be gained and applied in the field of genomics.Interdisciplinary skills will be gained including training in culture of M. tuberculosis and developmentof the SWGA approach. Finally, the results of this project could lead to new diagnostic tools, assistwith the management of the TB, and eventually benefit public health. The participation of St.George's Hospital and University will assist with the roll-out in a clinical setting of any sequencingor laboratory-based tools developed..
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
雷特综合症致病蛋白MeCP2在DNA损伤修复中的功能及分子机制研究
  • 批准号:
    32070780
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    刘红美
  • 依托单位:
组蛋白去乙酰化酶SirT7翻译后修饰及其在调控肿瘤耐药中的作用研究
  • 批准号:
    32070770
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    孙莲慧
  • 依托单位:
新的FANCM关联蛋白复合物FMAP150-FMAP160调控FANCM修复停滞复制叉的作用及机制
  • 批准号:
    32070716
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    ZHIJIANG YAN
  • 依托单位:
激活SENP1-Sirt3轴改善线粒体健康对延缓衰老的作用与机制研究
  • 批准号:
    92049113
  • 项目类别:
    重大研究计划
  • 资助金额:
    60.0万元
  • 批准年份:
    2020
  • 负责人:
    王田实
  • 依托单位: